Group 1 - The company Huason Pharmaceutical (002907.SZ) has announced that its product, Apsa-Rasagiline Tablets, has completed the domestic production drug filing with the National Medical Products Administration (NMPA) [1] - The filing includes an application for the drug's instructions to be adapted for elderly patients, which indicates a focus on improving accessibility for this demographic [1] - The registration information has been publicly disclosed on the NMPA's website, enhancing transparency regarding the company's product status [1]

Core Viewpoint - Huason Pharmaceutical (002907.SZ) has completed the domestic production registration of its product, Amlodipine Besylate Tablets, which includes an elderly-friendly drug instruction manual. This registration aims to enhance readability and usability, addressing the aging population trend, and is expected to improve market competitiveness and open new market opportunities, although it will not have a significant short-term impact on the company's performance [1]. Group 1 - The product Amlodipine Besylate Tablets is classified as a Category B drug under the national medical insurance system [1]. - The drug is indicated for the treatment of primary Parkinson's disease, both as a standalone treatment and as an adjunct to Levodopa [1]. - The registration includes both a simplified paper version and a complete electronic version of the drug instruction manual [1]. Group 2 - The registration is part of the company's strategy to respond to the aging population trend [1]. - The expected outcome of this registration is to enhance the product's market competitiveness [1]. - The company anticipates that this move will help in exploring new market opportunities [1].